Navigation Links
Despite Oncologists' Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
Date:2/11/2008

Seventy-nine Percent of U.S. Oncologists Currently Use Avastin to Treat the

Disease, According to a New Macroview Update from Decision Resources

WALTHAM, Mass., Feb. 11 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, reports that the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against Genentech/Roche's Avastin for first-line treatment of breast cancer in December 2007. According to the new Macroview update, the FDA's ODAC voted 5 to 4 that data are insufficient to recommend Avastin for approval for first-line treatment of metastatic or recurrent breast cancer.

The ODAC said that in the absence of a benefit in overall survival, Avastin's 5.5 month improvement in progression-free survival does not outweigh the risks associated with the drug.

An August 2007 survey by Decision Resources found that a very high rate of oncologists prescribing Avastin off-label to treat metastatic breast cancer.

"In August of 2007, 79 percent of U.S. oncologists were using Avastin to treat breast cancer patients," said Mary Fletcher-Louis., director at Decision Resources. "This prescribing behavior is driven by familiarity with Avastin for colorectal cancer and non-small-cell lung cancer, and by approval of this agent for breast cancer in Europe."

The FDA is not bound by the ODAC vote, and will make its final decision by February 23, 2008. For commentary on the final vote, please contact Elizabeth Marshall at 781-296-2563 to schedule an interview with Dr. Argent-Katwala.

About Macroview from Decision Resources

Macroview is the most up-to-date analysis on events impacting the healthcare industry. The Macroview updates are part of Decision Resources' Pharmaview product line, which offers a thorough analysis of the biopharmaceutical sector from a therapy, industry and company point-of-view.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Despite polarized opinions, Democrats and Republicans perform same amount of green actions
2. Physicians Still Hopeful About Desmoteplase for the Treatment of Acute Ischemic Stroke Despite Negative Results
3. Herons persist in Chicago wetlands despite exposure to banned chemicals
4. Despite efforts, significant racial disparities in cancer therapy still exist
5. Coshocton County Memorial Hospital RNs to Strike Despite Hospitals Claim of Financial Hardship
6. Miscarriage myths persist despite prevalence of medical information
7. Research finds allergic children exposed to peanuts at younger ages despite recommendations to avoid
8. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
9. A Full and Long Life, Despite Diabetes
10. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
11. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
Breaking Medicine Technology: